ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0800

Antibody Response to Shingrix Vaccination in Patients with Rheumatoid Arthritis, Seronegative Spondyloarthropathy and Systemic Lupus Erythematosus on Immunosuppressive Medications

Alina Kifayat1, amy Wasserman2, Kirk Sperber1, Deana Nes3, Paul Arnaboldi4 and Julia Ash5, 1New York Medical College at Westchester Medical Center, Valhalla, NY, 2New York Medical College at Westchester Medical Center, Armonk, NY, 3Bergen Medical Associates, Ridgewood, NJ, 4New York Medical College, Valhalla, NY, 5New York Medical College at Westchester Medical Center, Dobbs Ferry, NY

Meeting: ACR Convergence 2022

Keywords: Infection, prevention, rheumatoid arthritis, Spondyloarthropathies, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Infection-related Rheumatic Disease Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: In patients with rheumatic diseases herpes zoster (HZ) has been identified as one of the most common infections associated with immunosuppression. Shingrix is a recombinant inactive vaccine available for prevention of HZ infection. Due to paucity of data regarding its efficacy in patients with autoimmune disease on immunosuppressive medications, there is a need to investigate whether this patient population mounts an adequate response to Shingrix as compared to patients with no autoimmune disease and not on immunosuppressive medications.

Methods: Our study is an IRB approved single center prospective non randomized trial. Criteria for study group enrollment consisted of patients over age 50 with autoimmune conditions including rheumatoid arthritis(RA), psoriatic arthritis(PsA) and systemic lupus erythematosus(SLE) on bDMARDs, cDMARDs or tsDMARDs +/- steroids. Criteria for control group consisted of patients over age 50 without autoimmune diseases and not on immunosuppressive medications. At time of enrollment patients underwent bloodwork to establish a pre-vaccination serum antibody quantification. Patients then underwent two series of IM Shingrix vaccine (0.5mL each) administered 2 to 6 months apart. Repeat bloodwork was performed 6-12 weeks following 2nd dose of vaccine to assess post- vaccination antibody response. Pre and post vaccination response was then compared using Anti Varicella Zoster Virus IgG ELISA kit (Alpha diagnostic international). A level of 150 U/ml post vaccination was considered protective by the manufacturer of the kit.

Results: We enrolled a total of 29 patients out of which 23 were a part of study group and 6 were a part of the control group. Pre vaccine varicella IgG titers (U/ml) were obtained (pre-level; figure 1) followed by 2 doses of vaccination after which post vaccination varicella IgG titers (U/ml) were measured (post lvl; figure 1). Stimulation index (S.I=post lvl/pre-level) was calculated for individual patients to assess response. Stimulation index mean was calculated for each group for comparison.

Control group had 6.7 fold increase (S.I=6.7) in antibody titers in comparison to 2.4 fold increase in RA, 3.4 fold increase in PsA and 3.3 fold increase in SLE groups. (Fig 2a)

Control group had 6.7 fold increase in antibody titers compared to 2.1 fold increase in patients on biologics, 2.8 fold in patients on MTX and 3.4 fold in patients on steroids. (Fig 2b)

Overall, antibody titre response of control group patients was at least 3 times higher compared to patients with rheumatic diseases. (6.7 vs. 2.8). (Fig 2c)

Conclusion: Our study shows that patients with rheumatic diseases on treatment do mount a response to Shingrix vaccine but the increase in antibody titers is lower than controls.

Using a protective level of antibody titers at 150 U/ml, most rheumatic disease patients (91%) did reach a protective level of immunity supporting the need to offer Shingrix vaccination to our patients. The vaccine was well tolerated with no major adverse events.

Supporting image 1

Figure 1: Patient characteristics, pre and post levels and stimulation index

Supporting image 2

Figure 2: Stimulation index comparison by categories


Disclosures: A. Kifayat, None; a. Wasserman, None; K. Sperber, None; D. Nes, None; P. Arnaboldi, None; J. Ash, None.

To cite this abstract in AMA style:

Kifayat A, Wasserman a, Sperber K, Nes D, Arnaboldi P, Ash J. Antibody Response to Shingrix Vaccination in Patients with Rheumatoid Arthritis, Seronegative Spondyloarthropathy and Systemic Lupus Erythematosus on Immunosuppressive Medications [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/antibody-response-to-shingrix-vaccination-in-patients-with-rheumatoid-arthritis-seronegative-spondyloarthropathy-and-systemic-lupus-erythematosus-on-immunosuppressive-medications/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/antibody-response-to-shingrix-vaccination-in-patients-with-rheumatoid-arthritis-seronegative-spondyloarthropathy-and-systemic-lupus-erythematosus-on-immunosuppressive-medications/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology